Paclitaxel-induced dermal hypersensitivity lesions: 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography

• Published in: Lung India Vol. 35; no. 2; pp. 157 - 159
• Main Authors: Biner, Inci, Tatci, Ebru, Ozyurek, Berna, Ozmen, Ozlem
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.03.2018; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography; Cancer therapies; Care and treatment; Case Report; Case studies; CAT scans; Chemotherapy; Complications and side effects; Cytotoxicity; Diagnosis; Dosage and administration; hypersensitivity reaction; Lung cancer; Medical imaging; Metastasis; Nuclear medicine; Paclitaxel; Patients; Risk factors; Skin; Skin diseases; Surgery; Thoracic surgery; Tomography; Ankara Turkey; lung cancer; paclitaxel; hypersensitivity reaction; 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography
• ISSN: 0970-2113; 0974-598X
• DOI: 10.4103/lungindia.lungindia_189_17

Paclitaxel is frequently used for the treatment of patients with nonsmall cell lung cancer. Hypersensitivity reactions (HSRs) have been one of the toxicities observed with administration of paclitaxel. Here, we presented a case of a 49-year-old man with a history of right lung mass proven by biopsy to be a nonsmall cell lung cancer (squamous cell carcinoma) who developed HSR during therapy. In addition to the hypermetabolic primary malignancy, a positron emission tomography/computed tomography (PET/CT) scan showed multiple hypermetabolic skin lesions at several parts of the body. These cutaneous lesions were resolved in the restaging PET/CT scan performed after completion of the six cycles of chemotherapy. This is the first documented case of comparative PET/CT findings of a paclitaxel-induced hypersensitivity.